Immunotherapy in Allergic Rhinitis

Table of Contents

• ABOUT DATAMONITOR HEALTHCARE
  • About the Respiratory & Infectious Disease (RID)analysis team
• CHAPTER 1 EXECUTIVE SUMMARY
  • Scope
  • Datamonitor insight into the disease market
• CHAPTER 2 DISEASE BACKGROUND
  • Disease classification and epidemiology
    • Prevalence of AR
    • Historic trends in AR prevalence show increase
    • Costs of AR
  • Etiology
    • Minimal persistent inflammation
  • Symptoms and co-morbidities
    • Asthma is main and most important co-morbidity
  • Diagnosis
• CHAPTER 3 TREATMENT OPTIONS
  • Immunotherapy
  • Immunotherapy: an expanding market?
• CHAPTER 4 FUTURE TRENDS IN IMMUNOTHERAPY
  • Company overview
• CHAPTER 5 REFERENCES
  • Disclaimer
• List of Tables
  • Table 1: Prevalence of nasal allergy, 20−44 agegroup, Europe, 1996
  • Table 2: Diagnosed allergic rhinitis prevalence andpopulation by country, 2006, 2016
  • Table 3: Distribution of type of allergen in ARpatients
  • Table 4: The diagnosed AR population of over 20 yearsold according to severity and allergen in the seven major markets for2006 and 2016, in millions
  • Table 5: The diagnosed AR population of over 20 yearsold according to severity and allergen in the US for 2006 and 2016, inmillions
  • Table 6: The diagnosed AR population of over 20 yearsold according to severity and allergen in Europe for 2006 and 2016, inmillions
  • Table 7: The diagnosed AR population of over 20 yearsold according to severity and allergen in Japan for 2006 and 2016, inmillions
  • Table 8: Time trends in hay fever or allergic rhinitisin school age children in the UK, Finland, and Germany
  • Table 9: Heredity as a risk factor for allergicrhinitis
  • Table 10: Symptoms measured with a writtenquestionnaire in children aged 13−14 years in the seven majormarkets
  • Table 11: Allergic rhinitis treatment recommendationsby ARIA (2001)
  • Table 12: Novel AR immunotherapies in clinicaldevelopment
• List of Figures
  • Figure 1: Classification of allergic rhinitis is basedon duration and severity of symptoms
  • Figure 2: Age distribution of allergic rhinitis showspeak between 15 and 25 years old, Germany, 1995
  • Figure 3: Distribution of severity of diagnosed ARpatients
  • Figure 4: The allergic response in allergic rhinitis
  • Figure 5: Triggers of allergic rhinitis includeallergens, pollutants and aspirin
  • Figure 6: Concept of minimal persistent inflammation
  • Figure 7: Classification of the symptoms of allergicrhinitis
  • Figure 8: The diagnosis of AR relies on patienthistory and allergen tests
  • Figure 9: Treatment options in allergic rhinitisinclude allergen avoidance, pharmacotherapy and immunotherapy
  • Figure 10: Stepwise approach to the treatment ofallergic rhinitis
  • Figure 11: SIT is a niche market in the AR market
  • Figure 12: Three leading companies cover two-thirds ofSIT market
  • Figure 13: 13−38% of seasonal AR sufferers arenot suitable candidates for immunotherapy
  • Figure 14: Immunotherapy market in the treatment of ARhas opportunity to expand
  • Figure 15: Distribution of pipeline products accordingto Phase
  • Figure 16: Distribution of pipeline products accordingto allergen